A Study of Efficacy and Safety of TLL-018 in CSU Participants

NCT ID: NCT06396026

Last Updated: 2024-12-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 436 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-24
• Study Completion Date: 2027-12-30

Brief Summary

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.

Detailed Description

This is a randomized, double-blind, single-dummy, placebo-parallel-group, phase 3 study to assess the safety and efficacy of TLL-018 in Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) participants who had an Inadequate Controll to Second Generation H1-antihistamines.

Conditions

Chronic Spontaneous Urticaria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Arm 1

TLL018 tablets,1piece,BID

Group Type: EXPERIMENTAL

TLL-018 tablets

Intervention Type: DRUG

Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks

Arm 2

Placebo tablets,1piece,BID

Group Type: PLACEBO_COMPARATOR

Placebo tablets

Intervention Type: DRUG

Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.

Interventions

TLL-018 tablets

Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks

Intervention Type: DRUG

Placebo tablets

Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Aged between 18 and 75.
• Diagnosis of CSU refractory to secomd-generation H1-AH.
• CSU diagnosis for ≥ 6 months.
• The presence of itch and hivese despite current use of an approved dose of H1-AH prior to screening visit.
• UAS7 score (range 0-42) ≥ 16 and itch component of UAS7 (range 0-21) ≥ 8 during 7 days prior to randomization (Day 1).
• Participants were required to take a stable standard dose of a second generation H1-AH concomitantly according to local guidelines.
• Willing and able to complete UPDD for the duration of the study.
• Evidence of urticaria confirmed by the investigator prior to randomization.
• Women of Child Bearing Potential (WOCBP) should not be pregnant or breastfeeding and the pregnancy test should be negative before randomization.
• Participants (whether male or female) should have adequate barrier contraception during the whole treatment period and at least 90 days after treatment; subjects should avoid the sperm or ovum donation for at least six months after treatment.

Exclusion Criteria

• Participants meeting Chinese Guidelines for Urticaria Diagnosis and Treatment with the following concomitant diseases cannot be enrolled:

1. Clearly defined underlying etiology for chronic urticarias other than CSU. E.g. induced urticaria, including but not limited to artificial urticaria.

2. Any disease, which may have symptoms of urticaria and/or angioedema, including but not limited to urticaria and vasculitis.

3. Suffering from other chronic pruritic diseases that may affect the judgment of efficacy results, such as psoriasis, atopic dermatitis, etc.

4. Previous malignancy, herpes zoster, active tuberculosis.

5. Other symptoms of progressive or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, or cerebral disease.

6. Taking part in this study, in the opinion of the investigator, places the patient at unacceptable risk.

• Participants with any of the following prior therapies or concomitant medications cannot be enrolled:

1. Have received any study drug within 4 weeks or less than 5 elimination of half-life period before randomization (whichever is longer).

2. Have received biological agent within 3 months or 5 elimination of half-life period prior to randomization (whichever is longer).

3. Have received immunosuppressive/modulatory drug within 4 weeks before randomization.

4. Have received any live vaccine within 2 months before randomization or plan to receive a live vaccine during the study.

• Have experienced major surgery within 4 weeks before randomization, or expected to receive major surgical treatment after enrollment;
• Have donated blood more than 400 ml or received blood transfusion within 3 months prior to the study.
• History of drug or alcohol abuse within 6 months prior to screening.
• Allergy to ingredients or excipients of H1-AH or TLL-018.
• Laboratory test results are abnormal and may interfere the study judged by investigators.
• Participants are not appropriate for participation in any other situation or condition in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hangzhou Highlightll Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences

Nanjing, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Qianjin Lu, Ph.D

Role: CONTACT

Phone: +86-025-85478030

Email: qianlu5860@gmail.com

Facility Contacts

Qianjin Lu, Ph.D

Role: primary

Other Identifiers

TLL-018-303

Identifier Type: -

Identifier Source: org_study_id